Review



potent activity against a375  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC potent activity against a375
    The cytotoxic activity of 22a–22j and MTX against <t> A-375, </t> MCF7 and MDA-MB-468 and HEK-293 cell lines
    Potent Activity Against A375, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 5035 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/potent activity against a375/product/ATCC
    Average 99 stars, based on 5035 article reviews
    potent activity against a375 - by Bioz Stars, 2026-06
    99/100 stars

    Images

    1) Product Images from "Design, synthesis, anticancer and in silico assessment of 8-caffeinyl-triazolylmethoxy hybrid conjugates † "

    Article Title: Design, synthesis, anticancer and in silico assessment of 8-caffeinyl-triazolylmethoxy hybrid conjugates †

    Journal: RSC Advances

    doi: 10.1039/d2ra07683g

    The cytotoxic activity of 22a–22j and MTX against A-375, MCF7 and MDA-MB-468 and HEK-293 cell lines
    Figure Legend Snippet: The cytotoxic activity of 22a–22j and MTX against A-375, MCF7 and MDA-MB-468 and HEK-293 cell lines

    Techniques Used: Activity Assay

    (A) The viability assessment for 22a–22j and MTX against A375. (B) The viability assessment for 22a–22j and MTX against MCF7. (C) The viability assessment for 22a–22j and MTX against MDA-MB-468. (D) The viability assessment for 22a–22j and MTX against HEK-293.
    Figure Legend Snippet: (A) The viability assessment for 22a–22j and MTX against A375. (B) The viability assessment for 22a–22j and MTX against MCF7. (C) The viability assessment for 22a–22j and MTX against MDA-MB-468. (D) The viability assessment for 22a–22j and MTX against HEK-293.

    Techniques Used:



    Similar Products

    potent activity against a375  (ATCC)
    99
    ATCC potent activity against a375
    The cytotoxic activity of 22a–22j and MTX against <t> A-375, </t> MCF7 and MDA-MB-468 and HEK-293 cell lines
    Potent Activity Against A375, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/potent activity against a375/product/ATCC
    Average 99 stars, based on 1 article reviews
    potent activity against a375 - by Bioz Stars, 2026-06
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    The cytotoxic activity of 22a–22j and MTX against A-375, MCF7 and MDA-MB-468 and HEK-293 cell lines

    Journal: RSC Advances

    Article Title: Design, synthesis, anticancer and in silico assessment of 8-caffeinyl-triazolylmethoxy hybrid conjugates †

    doi: 10.1039/d2ra07683g

    Figure Lengend Snippet: The cytotoxic activity of 22a–22j and MTX against A-375, MCF7 and MDA-MB-468 and HEK-293 cell lines

    Article Snippet: The in vitro evaluations of synthesized compounds on cancer cell lines, including two breast cancer cell lines MDA-MB-468 (ATCC HTB-22), MCF-7 (ATCC HTB-22), melanoma cell line A-375 (ATCC CRL-1619) and normal cell line HEK-293 (ATCC CRL-11268) have determined that 22c (IC 50 < 12.5 μM) demonstrated potent activity against A375 and its toxicity is even stronger than methotrexate (MTX) as a standard drug.

    Techniques: Activity Assay

    (A) The viability assessment for 22a–22j and MTX against A375. (B) The viability assessment for 22a–22j and MTX against MCF7. (C) The viability assessment for 22a–22j and MTX against MDA-MB-468. (D) The viability assessment for 22a–22j and MTX against HEK-293.

    Journal: RSC Advances

    Article Title: Design, synthesis, anticancer and in silico assessment of 8-caffeinyl-triazolylmethoxy hybrid conjugates †

    doi: 10.1039/d2ra07683g

    Figure Lengend Snippet: (A) The viability assessment for 22a–22j and MTX against A375. (B) The viability assessment for 22a–22j and MTX against MCF7. (C) The viability assessment for 22a–22j and MTX against MDA-MB-468. (D) The viability assessment for 22a–22j and MTX against HEK-293.

    Article Snippet: The in vitro evaluations of synthesized compounds on cancer cell lines, including two breast cancer cell lines MDA-MB-468 (ATCC HTB-22), MCF-7 (ATCC HTB-22), melanoma cell line A-375 (ATCC CRL-1619) and normal cell line HEK-293 (ATCC CRL-11268) have determined that 22c (IC 50 < 12.5 μM) demonstrated potent activity against A375 and its toxicity is even stronger than methotrexate (MTX) as a standard drug.

    Techniques: